Diabetic foot infection in hospitalized adults

Journal of Infection and Chemotherapy

Volumn 22, Issue 3, 2016, Pages 167-173

  Katz, David E ^a   Friedman, N Deborah ^b   Ostrovski, Evgenia ^c   Ravid, Dor ^c   Amrami, Nadav ^c   Avivi, Dori ^c   Mengesha, Bethlehem ^c   Zaidenstein, Ronit ^c,d   Lazarovitch, Tsilia ^c   Dadon, Mor ^c   Marchaim, Dror ^c,d  

^a SHAARE ZEDEK MEDICAL CENTER   (Israel)

^b BARWON HEALTH   (Australia)

^c ASSAF HAROFEH MEDICAL CENTER   (Israel)

^d TEL AVIV UNIVERSITY   (Israel)

Author keywords

Antimicrobial resistance; DFI; Diabetes; Hyperbaric oxygen; Skin and soft tissue infections; SSTI

Indexed keywords

BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CEPHALOSPORIN DERIVATIVE; CLINDAMYCIN; HEMOGLOBIN A1C; METRONIDAZOLE; POLYPEPTIDE ANTIBIOTIC AGENT; QUINOLONE DERIVATIVE; ANTIINFECTIVE AGENT;

AGED; ANTIMICROBIAL THERAPY; ARTICLE; COHORT ANALYSIS; DESCRIPTIVE RESEARCH; DIABETIC FOOT; DIABETIC FOOT INFECTION; EMERGENCY CARE; FEMALE; GROUPS BY AGE; HEMOGLOBIN BLOOD LEVEL; HOSPITAL ADMISSION; HOSPITAL PATIENT; HOSPITAL READMISSION; HOSPITALIZATION COST; HUMAN; HYPERBARIC OXYGEN; INFECTION; LENGTH OF STAY; LIMB AMPUTATION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT; PERIPHERAL VASCULAR DISEASE; RETROSPECTIVE STUDY; TERTIARY CARE CENTER; HYPERBARIC OXYGEN THERAPY; ISRAEL; MICROBIOLOGY; MIDDLE AGED; MORTALITY; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; DIABETIC FOOT; FEMALE; HUMANS; HYPERBARIC OXYGENATION; ISRAEL; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84960287792     PISSN: 1341321X     EISSN: 14377780     Source Type: Journal    
DOI: 10.1016/j.jiac.2015.12.007     Document Type: Article

References (34)

1. Statistics about diabetes: data from the national diabetes statistics report 2014, 2014. A.D. Association (Ed.).
2. Zandman-Goddard G., Feldbrin Z., Ovadia S., Zubkov T., Lipkin A., Wainstein J. A multi-disciplinary approach to diabetic foot patients-an organizational model for the treatment of leg complications in diabetic patients. Harefuah 2011, 150:593-595. 616.
3. Bader M.S. Diabetic foot infection. Am Fam Physician 2008, 78:71-79.
4. Lipsky B.A. Osteomyelitis of the foot in diabetic patients. Clin Infect Dis 1997, 25:1318-1326.
5. Peters E.J., Lipsky B.A., Berendt A.R., Embil J.M., Lavery L.A., Senneville E., et al. A systematic review of the effectiveness of interventions in the management of infection in the diabetic foot. Diabetes Metab Res Rev 2012, 28(Suppl. 1):142-162.
6. Lipsky B.A., Berendt A.R., Cornia P.B., Pile J.C., Peters E.J., Armstrong D.G., et al. 2012 infectious diseases society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections. Clin Infect Dis 2012, 54:e132-e173.
7. Giurini J.M., Lyons T.E. Diabetic foot complications: diagnosis and management. Int J Low Extrem Wounds 2005, 4:171-182.
8. Lipsky B.A. A current approach to diabetic foot infections. Curr Infect Dis Rep 1999, 1:253-260.
9. Slater R.A., Lazarovitch T., Boldur I., Ramot Y., Buchs A., Weiss M., et al. Swab cultures accurately identify bacterial pathogens in diabetic foot wounds not involving bone. Diabet Med 2004, 21:705-709.
10. Dellit T.H., Owens R.C., McGowan J.E., Gerding D.N., Weinstein R.A., Burke J.P., et al. Infectious diseases society of America and the society for healthcare epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 2007, 44:159-177.
11. Tamir E. Treating the diabetic ulcer: practical approach and general concepts. Isr Med Assoc J 2007, 9:610-615.
12. Weiss A., Karpf A., Luger E., Schmilowitz H., Dekel S., Shapira I. Long-term antibiotic treatment in geriatric diabetic foot infection. J Med 1998, 29:365-373.
13. Efrati S., Gall N., Bergan J., Fishlev G., Bass A., Berman S., et al. Hyperbaric oxygen, oxidative stress, no bioavailability and ulcer oxygenation in diabetic patients. Undersea Hyperb Med 2009, 36:1-12.
14. Charlson M.E., Pompei P., Ales K.L., MacKenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987, 40:373-383.
15. Lavery L.A., Armstrong D.G., Harkless L.B. Classification of diabetic foot wounds. J Foot Ankle Surg 1996, 35:528-531.
16. Hartemann-Heurtier A., Robert J., Jacqueminet S., Ha Van G., Golmard J.L., Jarlier V., et al. Diabetic foot ulcer and multidrug-resistant organisms: risk factors and impact. Diabet Med 2004, 21:710-715.
17. Kandemir O., Akbay E., Sahin E., Milcan A., Gen R. Risk factors for infection of the diabetic foot with multi-antibiotic resistant microorganisms. J Infect 2007, 54:439-445.
18. Citron D.M., Goldstein E.J., Merriam C.V., Lipsky B.A., Abramson M.A. Bacteriology of moderate-to-severe diabetic foot infections and in vitro activity of antimicrobial agents. J Clin Microbiol 2007, 45:2819-2828.
19. Paul M., Shani V., Muchtar E., Kariv G., Robenshtok E., Leibovici L. Systematic review and meta-analysis of the efficacy of appropriate empiric antibiotic therapy for sepsis. Antimicrob Agents Chemother 2010, 54:4851-4863.
20. Bonten M.J. Colonization pressure: a critical parameter in the epidemiology of antibiotic-resistant bacteria. Crit Care 2012, 16:142.
21. Edmonds M., Foster A. The use of antibiotics in the diabetic foot. Am J Surg 2004, 187:25S-28S.
22. Baquero F., Negri M.C., Morosini M.I., Blazquez J. Antibiotic-selective environments. Clin Infect Dis 1998, 27(Suppl. 1):S5-S11.
23. Schwaber M.J., Carmeli Y. An ongoing national intervention to contain the spread of carbapenem-resistant enterobacteriaceae. Clin Infect Dis 2014, 58:697-703.
24. Abbo A., Carmeli Y., Navon-Venezia S., Siegman-Igra Y., Schwaber M.J. Impact of multi-drug-resistant acinetobacter baumannii on clinical outcomes. Eur J Clin Microbiol Infect Dis 2007, 26:793-800.
25. Bogan C., Kaye K.S., Chopra T., Hayakawa K., Pogue J.M., Lephart P.R., et al. Outcomes of carbapenem-resistant enterobacteriaceae isolation: matched analysis. Am J Infect Control 2014, 42:612-620.
26. Cosgrove S.E., Qi Y., Kaye K.S., Harbarth S., Karchmer A.W., Carmeli Y. The impact of methicillin resistance in staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges. Infect Control Hosp Epidemiol 2005, 26:166-174.
27. Schwaber M.J., Carmeli Y. Antimicrobial resistance and patient outcomes: the hazards of adjustment. Crit Care 2006, 10:164.
28. Schwaber M.J., Navon-Venezia S., Kaye K.S., Ben-Ami R., Schwartz D., Carmeli Y. Clinical and economic impact of bacteremia with extended- spectrum-beta-lactamase-producing enterobacteriaceae. Antimicrob Agents Chemother 2006, 50:1257-1262.
29. Tacconelli E., De Angelis G., Cataldo M.A., Mantengoli E., Spanu T., Pan A., et al. Antibiotic usage and risk of colonization and infection with antibiotic-resistant bacteria: a hospital population-based study. Antimicrob Agents Chemother 2009, 53:4264-4269.
30. Faglia E., Favales F., Aldeghi A., Calia P., Quarantiello A., Oriani G., et al. Adjunctive systemic hyperbaric oxygen therapy in treatment of severe prevalently ischemic diabetic foot ulcer. A randomized study. Diabetes Care 1996, 19:1338-1343.
31. Margolis D.J., Gupta J., Hoffstad O., Papdopoulos M., Glick H.A., Thom S.R., et al. Lack of effectiveness of hyperbaric oxygen therapy for the treatment of diabetic foot ulcer and the prevention of amputation: a cohort study. Diabetes Care 2013, 36:1961-1966.
32. Berendt A.R. Counterpoint: hyperbaric oxygen for diabetic foot wounds is not effective. Clin Infect Dis 2006, 43:193-198.
33. Boulton A.J., Vileikyte L., Ragnarson-Tennvall G., Apelqvist J. The global burden of diabetic foot disease. Lancet 2005, 366:1719-1724.
34. Bion J.F., Edlin S.A., Ramsay G., McCabe S., Ledingham I.M. Validation of a prognostic score in critically ill patients undergoing transport. Br Med J 1985, 291:432-434. (Clin Res Ed).